Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder
Name	Attention Deficit Hyperactivity Disorder
Synonyms	ADHD
Field	Psychiatry, Neurology, Pediatrics
Symptoms	Inattention, hyperactivity, impulsivity
Onset	Childhood
Medication	Stimulants, nonstimulants
Frequency	~5–7% children, ~2–5% adults

Attention Deficit Hyperactivity Disorder is a neurodevelopmental condition characterized by persistent patterns of inattention, hyperactivity, and impulsivity that impair functioning across contexts. Descriptions of the condition appear in clinical manuals such as the Diagnostic and Statistical Manual of Mental Disorders and the International Classification of Diseases, and it is the subject of research by institutions including the National Institute of Mental Health, World Health Organization, and universities such as Harvard University and University of Cambridge.

Signs and symptoms

Core features include inattention, hyperactivity, and impulsivity observed in settings such as home, school, and workplace. Inattention manifests as distractibility, poor sustained effort, and forgetfulness noted by clinicians referencing instruments like the Conners' Rating Scales, Child Behavior Checklist, and reports from practitioners at centers such as Mayo Clinic and Cleveland Clinic. Hyperactivity appears as excessive motor activity, fidgeting, or inability to remain seated during tasks described in case series from Johns Hopkins Hospital and cohort studies from Karolinska Institutet. Impulsivity shows as interrupting, impatience, and risky decision-making documented in longitudinal cohorts at University of California, Los Angeles and King's College London. Comorbidities often include Major depressive disorder, Generalized anxiety disorder, Oppositional defiant disorder, Autism spectrum disorder, and substance use disorders reported in meta-analyses by groups at Yale University, University of Oxford, and Stanford University. Functional impacts extend to academic underachievement reported by researchers at Columbia University, occupational impairment documented by analysts at Princeton University, and interpersonal difficulties studied at University of Toronto.

Causes and risk factors

Etiology is multifactorial with genetic, neurobiological, and environmental contributors investigated by consortia such as the Psychiatric Genomics Consortium and teams at Broad Institute. Heritability estimates derive from twin studies by researchers at King's College London and University of California, Berkeley implicating genes affecting dopamine signaling including variants near genes studied at Cold Spring Harbor Laboratory and Salk Institute. Neuroimaging from groups at Massachusetts General Hospital, University College London, and McGill University shows differences in prefrontal cortex, basal ganglia, and cerebellar circuits paralleling findings in studies by National Institutes of Health. Perinatal risks such as low birth weight, prenatal exposure to tobacco or alcohol, and prematurity are reported in population cohorts from Duke University, University of Michigan, and University of Sydney. Environmental associations, including psychosocial adversity and lead exposure, were examined by teams at University of Pittsburgh, London School of Hygiene and Tropical Medicine, and University of Cape Town. Pharmacologic exposures and diet have been assessed in trials at University of Oxford, University of Edinburgh, and University of Washington without consensus on single causal factors.

Diagnosis and classification

Diagnostic criteria follow the Diagnostic and Statistical Manual of Mental Disorders editions and the International Classification of Diseases coding used in clinics such as Boston Children's Hospital and Great Ormond Street Hospital. Classification distinguishes inattentive, hyperactive-impulsive, and combined presentations described in textbooks from Cambridge University Press and guideline documents from American Academy of Pediatrics, National Institute for Health and Care Excellence, and American Psychiatric Association. Assessment integrates clinical interview, standardized rating scales (e.g., Vanderbilt ADHD Diagnostic Rating Scale), and collateral information from schools like Public Schools and family settings, with differential diagnosis considering conditions evaluated at specialty centers including Mayo Clinic and Sheffield Children's NHS Foundation Trust. Age of onset, symptom pervasiveness, and impairment inform diagnosis in multidisciplinary teams at institutions such as Boston Medical Center and Johns Hopkins Hospital.

Management and treatment

Treatment uses multimodal approaches combining pharmacotherapy, psychosocial interventions, and educational accommodations promoted by agencies like American Academy of Pediatrics, National Institute for Health and Care Excellence, and World Health Organization. First-line medications often include stimulant agents (methylphenidate, amphetamines) whose efficacy was demonstrated in randomized trials at Vanderbilt University, University of Toronto, and Columbia University, and nonstimulant options such as atomoxetine and guanfacine studied at AstraZeneca-sponsored trials and university centers. Behavioral therapies include parent training programs developed at Johns Hopkins University and school-based interventions implemented in districts like New York City Department of Education and Los Angeles Unified School District. Educational accommodations follow plans modeled on frameworks from Individuals with Disabilities Education Act and school health services in systems studied by researchers at University of California, Berkeley and University of Michigan. Emerging interventions under study at Massachusetts Institute of Technology, Imperial College London, and Karolinska Institutet include neurofeedback, digital therapeutics, and cognitive training.

Epidemiology and prognosis

Prevalence estimates vary by region and methodology with systematic reviews from World Health Organization, Centers for Disease Control and Prevention, and meta-analyses by teams at University of Oxford reporting childhood prevalence around 5–7% and adult prevalence around 2–5%. Incidence and persistence have been documented in longitudinal cohorts from Dunedin Study at University of Otago, the Avon Longitudinal Study of Parents and Children at University of Bristol, and birth cohorts at University of Helsinki. Prognosis is heterogeneous: some individuals show symptom remittance by adulthood described in studies at University of Cambridge while others experience ongoing impairment linked to outcomes in research from Harvard Medical School, Yale School of Medicine, and Columbia University Medical Center. Risks include academic underachievement, occupational instability, and increased accident rates documented in national registries from Sweden and Denmark.

Research and controversies

Active research areas include genetics led by the Psychiatric Genomics Consortium, neuroimaging consortia at ENIGMA, and trials of novel pharmacotherapies and digital treatments at NIH and industry partners such as Pfizer and Novartis. Controversies encompass diagnostic expansion debated in commentary from New England Journal of Medicine and policy analyses by The Lancet, concerns about overprescription reported in investigations involving healthcare systems like NHS and insurers including UnitedHealth Group, and debates on stimulant safety reviewed by regulatory agencies such as the U.S. Food and Drug Administration and European Medicines Agency. Ethical discussions about labeling, educational policy, and resource allocation feature contributions from scholars at Oxford University, Harvard Kennedy School, and Brookings Institution.

Category:Neurodevelopmental disorders